JP2016528195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528195A5 JP2016528195A5 JP2016523819A JP2016523819A JP2016528195A5 JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5 JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839170P | 2013-06-25 | 2013-06-25 | |
| US61/839,170 | 2013-06-25 | ||
| US201361874241P | 2013-09-05 | 2013-09-05 | |
| US61/874,241 | 2013-09-05 | ||
| US201361884771P | 2013-09-30 | 2013-09-30 | |
| US61/884,771 | 2013-09-30 | ||
| US201361907845P | 2013-11-22 | 2013-11-22 | |
| US61/907,845 | 2013-11-22 | ||
| PCT/US2014/043466 WO2014209802A1 (en) | 2013-06-25 | 2014-06-20 | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Division JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528195A JP2016528195A (ja) | 2016-09-15 |
| JP2016528195A5 true JP2016528195A5 (https=) | 2017-07-27 |
| JP6611709B2 JP6611709B2 (ja) | 2019-11-27 |
Family
ID=52142579
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523819A Active JP6611709B2 (ja) | 2013-06-25 | 2014-06-20 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9828435B2 (https=) |
| EP (2) | EP3656392A1 (https=) |
| JP (3) | JP6611709B2 (https=) |
| KR (2) | KR102291971B1 (https=) |
| CN (1) | CN105492016B (https=) |
| AU (2) | AU2014302812B2 (https=) |
| BR (1) | BR112015032690B1 (https=) |
| CA (2) | CA3098741C (https=) |
| DK (1) | DK3013350T3 (https=) |
| EA (1) | EA036591B1 (https=) |
| ES (1) | ES2782834T3 (https=) |
| IL (1) | IL243301B (https=) |
| MX (1) | MX377858B (https=) |
| NZ (1) | NZ631015A (https=) |
| PL (1) | PL3013350T3 (https=) |
| PT (1) | PT3013350T (https=) |
| SG (2) | SG10201902380SA (https=) |
| WO (1) | WO2014209802A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2015167616A1 (en) * | 2014-05-02 | 2015-11-05 | Nitor Therapeutics | Guanosine as an immunepotentiator mediated through toll receptors |
| US10973843B2 (en) | 2016-01-27 | 2021-04-13 | University Of Maryland, Baltimore | Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens |
| US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US10884000B2 (en) * | 2016-04-18 | 2021-01-05 | Faron Pharmaceuticals Oy | Method of monitoring the efficacy of the anti-clever-1 therapy in cancer |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| EP3473262A4 (en) * | 2016-06-16 | 2020-03-18 | The University Of Tokyo | PLEXIN BINDING REGULATOR |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| USD889258S1 (en) * | 2016-08-04 | 2020-07-07 | Carolin McKie | Beverage container identification marker kit |
| AU2017326003A1 (en) * | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| CN110072540B (zh) * | 2016-10-12 | 2023-06-02 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| BR112019019597A2 (pt) * | 2017-03-20 | 2020-04-14 | Vaccinex Inc | tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2018204895A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| MX2021011799A (es) * | 2019-03-28 | 2021-10-26 | Vaccinex Inc | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. |
| EP3986446A1 (en) * | 2019-06-21 | 2022-04-27 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| WO2021024020A1 (en) * | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN111158663B (zh) * | 2019-12-26 | 2021-07-02 | 深圳逻辑汇科技有限公司 | 用于处理程序代码中的变量的引用的方法和系统 |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| WO2022040628A1 (en) * | 2020-08-21 | 2022-02-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin |
| CN112233123B (zh) * | 2020-09-21 | 2024-05-14 | 广州金域医学检验中心有限公司 | 病理图片中肿瘤间质分类方法、装置、计算机设备及存储介质 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
| CN117802242A (zh) * | 2024-01-22 | 2024-04-02 | 深圳慕光生物科技有限公司 | 一种利用sema4d基因预测肿瘤免疫逃避风险的方法 |
| WO2026080818A1 (en) * | 2024-10-10 | 2026-04-16 | Vaccinex, Inc. | Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| CA2548180C (en) | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| EP1773885B1 (en) * | 2004-08-05 | 2010-04-21 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節 |
| NZ586544A (en) | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| MX2011012147A (es) * | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| NZ604464A (en) | 2010-06-14 | 2014-03-28 | Vaccinex Inc | Anti-vegf antibodies and uses thereof |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| KR102003571B1 (ko) | 2011-05-13 | 2019-07-24 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 골형성 촉진제 |
| RU2014117952A (ru) | 2011-10-06 | 2015-11-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела против sema4a человека, используемые для лечения заболевания |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| CA2762446C (en) * | 2011-12-06 | 2021-02-23 | Vaccinex, Inc. | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP2951204B1 (en) | 2013-01-31 | 2019-05-22 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| MX377858B (es) * | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| CN110325213A (zh) | 2017-02-22 | 2019-10-11 | 瓦西尼斯公司 | 神经退行性或神经炎性疾病中胶质细胞活化的早期检测 |
-
2014
- 2014-06-20 MX MX2015017485A patent/MX377858B/es unknown
- 2014-06-20 KR KR1020167001991A patent/KR102291971B1/ko active Active
- 2014-06-20 NZ NZ631015A patent/NZ631015A/en unknown
- 2014-06-20 ES ES14818498T patent/ES2782834T3/es active Active
- 2014-06-20 CN CN201480047166.7A patent/CN105492016B/zh active Active
- 2014-06-20 JP JP2016523819A patent/JP6611709B2/ja active Active
- 2014-06-20 CA CA3098741A patent/CA3098741C/en active Active
- 2014-06-20 EA EA201690080A patent/EA036591B1/ru unknown
- 2014-06-20 US US14/892,099 patent/US9828435B2/en active Active
- 2014-06-20 WO PCT/US2014/043466 patent/WO2014209802A1/en not_active Ceased
- 2014-06-20 US US14/310,848 patent/US9243068B2/en active Active
- 2014-06-20 CA CA2916245A patent/CA2916245C/en active Active
- 2014-06-20 PL PL14818498T patent/PL3013350T3/pl unknown
- 2014-06-20 SG SG10201902380SA patent/SG10201902380SA/en unknown
- 2014-06-20 KR KR1020217025537A patent/KR20210104166A/ko not_active Ceased
- 2014-06-20 DK DK14818498.9T patent/DK3013350T3/da active
- 2014-06-20 BR BR112015032690-0A patent/BR112015032690B1/pt active IP Right Grant
- 2014-06-20 EP EP19209162.7A patent/EP3656392A1/en active Pending
- 2014-06-20 AU AU2014302812A patent/AU2014302812B2/en active Active
- 2014-06-20 SG SG11201510505VA patent/SG11201510505VA/en unknown
- 2014-06-20 EP EP14818498.9A patent/EP3013350B1/en active Active
- 2014-06-20 PT PT148184989T patent/PT3013350T/pt unknown
-
2015
- 2015-12-23 IL IL243301A patent/IL243301B/en active IP Right Grant
-
2017
- 2017-08-01 US US15/666,133 patent/US10526414B2/en active Active
-
2019
- 2019-04-23 US US16/392,451 patent/US11078295B2/en active Active
- 2019-07-11 JP JP2019129005A patent/JP7021153B2/ja active Active
- 2019-07-26 AU AU2019208274A patent/AU2019208274A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,020 patent/US12070500B2/en active Active
-
2022
- 2022-02-03 JP JP2022015562A patent/JP7356531B2/ja active Active
-
2024
- 2024-07-18 US US18/777,075 patent/US20250032609A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528195A5 (https=) | ||
| Lazăr et al. | Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP2021512914A5 (https=) | ||
| Bell et al. | OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment | |
| Parmar et al. | Immunotherapy in head and neck squamous cell carcinoma: An updated review | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP2019519499A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| CN108473578A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| JP2016525117A5 (https=) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| KR20220082097A (ko) | 방사선 치료와 조합된 ｐｄ-1 및 ｐｄ-ｌ1에 대한 길항제를 이용하는 암 치료 방법 | |
| JP2018503365A5 (https=) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2017120063A (ru) | Терапевтические комбинации для лечения неоплазии | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JPWO2019157332A5 (https=) | ||
| JPWO2020067085A1 (ja) | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 | |
| Cohen et al. | Therapeutic combinations of immune-modulating antibodies in melanoma and beyond |